Traws Pharma Delays Influenza Prophylaxis Study Amid MHRA Data Request
Event summary
- Traws Pharma expects to resubmit updated toxicology data for tivoxavir marboxil (TXM) to the MHRA in Q3 2026 after receiving additional feedback.
- The Phase 2a human influenza Challenge study is pending MHRA approval, with a formal response expected within 30 days of resubmission.
- TXM demonstrated broad in vitro efficacy against multiple seasonal influenza strains and favorable pharmacokinetic properties for chemoprophylaxis.
- Traws will also initiate profiling of additional molecules for its influenza treatment program.
The big picture
Traws Pharma’s delay in submitting updated toxicology data highlights the regulatory scrutiny facing novel antiviral therapies. The company is positioning TXM as a potential oral prophylaxis for seasonal influenza, a market with significant unmet needs, particularly for vulnerable populations. Success in this program could expand Traws’ portfolio beyond COVID-19 and into broader respiratory viral threats.
What we're watching
- Regulatory Timing
- Whether the MHRA will approve the updated data package within the expected 30-day window, clearing the path for the Phase 2a study.
- Clinical Efficacy
- How TXM’s proof-of-concept data in the influenza Challenge study will position it against existing prophylactic treatments.
- Pipeline Expansion
- The pace at which Traws advances additional molecules for its broader antiviral portfolio, including H5N1 bird flu and other negative-strand RNA viruses.